16 results
PRE 14A
ANEB
Anebulo Pharmaceuticals Inc
19 Oct 23
Preliminary proxy
5:18pm
stage biotechnology company developing therapeutics targeting chronic and age-related diseases, from November 2014 to March 2022. From December 2012
DEFR14A
ANEB
Anebulo Pharmaceuticals Inc
25 Oct 22
Revised proxy
5:27pm
for the treatment of chronic and age-related diseases, from March 2016 to December 2018. Mr. Allen was a consultant to Solstice Biologics, a biotechnology … , Inc., a publicly traded clinical stage biotechnology company developing therapeutics targeting chronic and age-related diseases, from November 2014
8-K
plt15lnr6782bs8
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
8-K
EX-99.1
0zt289oy
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
8-K
saudjl6ocven3fr22
5 Jan 22
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen
10:00am
10-K
pu9b9
22 Sep 21
Annual report
4:45pm
424B4
yw1 l0uqayezl
10 May 21
Prospectus supplement with pricing info
4:52pm
S-1/A
6yj0fr56 81
26 Apr 21
IPO registration (amended)
4:38pm
S-1
wb77v5 g516spca
1 Apr 21
IPO registration
5:19pm
DRS/A
zkqfjww65r j4d7ekst9
12 Mar 21
Draft registration statement (amended)
12:00am
DRS
gl8wlg3qfu6v5kvxm
29 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next